Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. cadiss

CADISS SIGNED

A medical device for the selective dissection of pathological tissues and fibrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CADISS project word cloud

Explore the words cloud of the CADISS project. It provides you a very rough idea of what is the project "CADISS" about.

dissecting    health    save    shorter    mesna    damaged    plane    anesthesia    grow    million    relying    dissection    period    surgically    cadiss    true    reaching    surgery    carefully    adhesion    disease    time    attributed    healthy    valued    2016    weakens    2025    global    occupation    cagr    billion    launch    expansion    international    revolutionary    size    reducing    countries    patients    cutting    minimizing    organ    topical    damage    consisting    risks    whereby    separated    150    9m    chemical    company    drug    rooms    pioneer    risk    thereby    hospital    either    separation    least    surgeries    23    surrounding    hospitals    tools    difficulties    relapse    people    tearing    replace    tissue    saves    optimize    30    surgical    combines    10    assisted    optimal    found    critical    involve    chemically    money    incidence    repair    sub    auxin    despite    pathological    complications    undergo    market    force    surgeon    remove    treatable    burden    mechanical    tissues    space    damages    selective    revenues    cleavage    5    amounting    diseased   

Project "CADISS" data sheet

The following table provides information about the project.

Coordinator		 AUXIN SURGERY 

Organization address
address: RUE LOUIS DE GEER 6
city: LOUVAIN LA NEUVE
postcode: 1348
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AUXIN SURGERY BE (LOUVAIN LA NEUVE) coordinator 50˙000.00

Map

 Project objective

Surgery is the art of dissecting tissues in order to repair, remove, or replace a diseased or damaged organ. 30% of the global burden of disease can be attributed to surgically treatable conditions. More than 10% of surgical procedures involve critical dissection steps whereby the pathological tissue is carefully separated from the healthy surrounding tissues. These procedures together have an incidence of 150/100.000 people, amounting for 2 million surgeries per year in developed countries. Despite the importance of selective dissection in surgical procedures, the current tools are sub-optimal because they are all still relying either on tearing force or on non-selective cutting that can damage tissues. Auxin Surgery, a pioneer in novel dissection methods, has found a revolutionary system, CADISS, that combines mechanical force with the topical application of a chemical drug, Mesna that weakens adhesion between tissues thereby facilitating the dissection steps and minimizing the damages to health tissues. CADISS saves time, therefore patients need to undergo anesthesia for shorter period, thereby reducing the risks of complications. Moreover, hospitals save money on the usage of operating rooms and hospital personnel and can optimize the occupation of hospital space. The global general surgery devices market size was valued at over €10 billion in 2016 and is expected to grow at a CAGR of 8.5% by 2025. Chemically assisted dissection can be useful in most surgical procedures consisting in separation of two tissues along a cleavage plane and when at least one of these conditions is true: 1) the risk of relapse is present 2) the risk of side-effects through damage of healthy tissue is present or 3) the risk of facing difficulties for the surgeon is present. CADISS will bring our company to international expansion and growth reaching €23.9M in revenues 3 years after market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CADISS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CADISS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More